Adam Giermasz, M.D., Ph.D.
Associate Professor of Medicine
To see if Adam Giermasz is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Specialties
Adult Hemophilia
Benign and Malignant Hematology
Thrombosis
Internal Medicine
Hematology/Oncology
Department
Locations and Contact
UC Davis Midtown Ambulatory Care Center
Midtown Multi Specialty
3160 Folsom Blvd
Sacramento, CA 95816
Additional Numbers
Clinic Phone
Clinic Fax
Physician Referrals
Philosophy of Care
Dr. Giermasz believes in high quality, innovative, and compassionate care of his patients. Dr. Giermasz believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Clinical Interests
Adam Giermasz co-directs the Hemophilia Treatment Center. He specializes in hemophilia, coagulation and thrombosis disorders.
Research/Academic Interests
Dr. Giermasz' research includes studies in new therapeutics with use of next generation clotting factor, bypassing agents and gene therapy; in addition he is interested in clinical projects aiming for quality of life improvement in patients with bleeding disorders.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.S., Biology, Chemistry, III Secondary School - Lyceum, Warsaw, Poland 1992
Medical School
M.D., Medical University of Warsaw, Warsaw, Poland 1998
Other School
Ph.D., Medical University of Warsaw, Warsaw, Poland 2002
Internship
Medicine, Military School of Medicine, Warsaw, Poland 1998-1999
Internship
Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2005-2006
Residency
Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2006-2008
Fellowship
Hematology/Oncology, UC San Francisco Medical Center, San Francisco CA 2008-2011
Top 10 Clinical Research Achievement Award for coauthored NEJM publication: "Hemophilia B Gene Therapy”, 2019
Annual Teaching Award, Medical University of Warsaw, 2000
National award and grant for young scholars of The Foundation for Polish Science (FNP), 2000
Scientific Award, Medical University of Warsaw, 1998
To view a detailed list of Dr. Giermasz's publications, please click here.
Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi:10.1056/NEJMoa2113708. PMID:35294811.
Escobar M, Luck J, Averianov Y, Ducore J, Fernández MFL, Giermasz A, Hart DP, Journeycake J, Kessler C, Leissinger C, Mahlangu J, Martinez LV, Miesbach W, Mitha IH, Quon D, Reding MT, Schved JF, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell IS, Wilkinson TA, Hermans C. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov;27(6):911-920. doi:10.1111/hae.14418. Epub 2021 Oct 6. PMID:34614267.
Rosen S, Tiefenbacher S, Robinson M, Huang M, Srimani J, Mackenzie D, Christianson T, Pasi KJ, Rangarajan S, Symington E, Giermasz A, Pierce GF, Kim B, Zoog SJ, Vettermann C. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. Blood. 2020 Nov 26;136(22):2524-2534. doi:10.1182/blood.2020005683. PMID:32915950.
Von Drygalski A, Giermasz A, Castaman G, Key NS, Lattimore S, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Sawyer EK, Pipe SW. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019 Nov 12;3(21):3241-3247. doi:10.1182/bloodadvances.2019000811. Erratum in: Blood Adv. 2020 Aug 11;4(15):3668. PMID:31698454.
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi:10.1056/NEJMoa1708538. PMID:29211678.
Tobase P, Mahajan A, Francis D, Leavitt AD, Giermasz A. A gap in comprehensive care: Sexual health in men with haemophilia. Haemophilia. 2017 Jul;23(4):e389-e391. doi:10.1111/hae.13276. Epub 2017 Jun 2. PMID:28574623.
Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz, A, Mancuso ME, Serban M, Tsay W, Mahlangu JN. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan;23(1):67-76. doi:10.1111/hae.13041. Epub 2016 Aug 1. PMID:27480487.
Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz, AS, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine. 2012 Mar 30;30(16):2633-9. doi:10.1016/j.vaccine.2012.02.026. Epub 2012 Feb 22. PMID:22365841.
Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009 Aug;58(8):1329-36. doi:10.1007/s00262-008-0648-5. Epub 2009 Jan 21. PMID:19156413.